ArticleAnnals of hematology2025

Ravulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration.

Zoe Bezirgiannidou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.